CoChat

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Open access
Gul, Anita, Stewart, Tyler F., Mantia, Charlene M., Shah, Neil J., Gatof, Emily Stern, Long, Ying, Allman, Kimberly D., Ornstein, Moshe C., Hammers, Hans J., McDermott, David F., Atkins, Michael B., Hurwitz, Michael, Rini, Brian I. · 2020 · Journal of Clinical Oncology
Cited by 98

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

PURPOSE: Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti–PD-1 pathway–targeted therapy. PATIENTS AND METHODS: Patients with metastatic RCC who received prior anti–PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed. RESULTS: Forty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients. CONCLUSION: Ipilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.03315

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×

    “Nivolumab, an anti–PD-1 antibody, was initially approved asmonotherapy after failure of prior VEGFpathway– directed therapy.(4) More recently, the combination of nivolumab and ipilimumab, an anti–CTLA-4 antibody, was approved in the first-line setting for patients with International Metastatic Database Consortium (IMD…”
    BackgroundSelf-citation
  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 1×

    “More recently, the combination of nivolumab and ipilimumab, an anti–CTLA-4 antibody, was approved in the first-line setting for patients with International Metastatic Database Consortium (IMDC) intermediate- and poor-risk disease on the basis of objective response rate (ORR) and overall survival advantages compared wi…”
    BackgroundSelf-citation
  • T cell exhaustion

    Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×

    “PD-1 blockade works during the effector phase and restores the immune function of T cells, which are exhausted as a result of high antigen exposure, as in advanced cancers.(11,12) CTLA-4 blockade induces a proliferative gene expression signature predominantly in a subset of transitional memory T cells, whereas PD-1 bl…”
    Background
  • Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

    Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403 · cited 8×

    “Ipilimumab and nivolumab have been evaluated in previously treated patients with metastatic RCC.9 Approximately one third of the patients enrolled in CheckMate 016 had prior treatment with cytokines, and 19% had prior VEGF receptor inhibitor treatment, but none of the patients had prior exposure to ICIs.”
    BackgroundInfluentialSelf-citation

Show all 4 references

Cited by

Metadata

Authors
Gul, A., Stewart, T. F., Mantia, C. M., Shah, N. J., Gatof, E. S., Long, Y., Allman, K. D., Ornstein, M. C., Hammers, H. J., McDermott, D. F., Atkins, M. B., Hurwitz, M., & Rini, B. I.
Venue
Journal of Clinical Oncology
Published
2020-09-20
Volume
38
Issue
27
Pages
3088-3094
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3028977302
Cited by
98
References
4
FWCI
5.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.